✦ LIBER ✦

Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors

✍ Scribed by Xing, Wen-Jing; Zou, Yan; Han, Qing-Lian; Dong, Yu-Cui; Deng, Zhen-Ling; Lv, Xiao-Hong; Jiang, Tao; Ren, Huan

Book ID: 119824796
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 688 KB
Volume: 40
Category: Article
ISSN: 0305-1870
DOI: 10.1111/1440-1681.12026

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The effects of type beta transforming gr

The effects of type beta transforming growth factor on proliferation and epidermal growth factor receptor expression in a human glioblastoma cell line

✍ Eirik Helseth; Geirmund Unsgaard; Are Dalen; Randi Vik 📂 Article 📅 1988 🏛 Springer US 🌐 English ⚖ 582 KB

Type beta transforming growth factor (B-TGF) is a potent growth inhibitor to many human tumor cell lines. Very little is known about the mechanism for this growth inhibitory action of B-TGF. We here report the effect of B-TGF on proliferation and epidermal growth factor receptor (R-EGF) expression i

Effects of Growth Factors and Basement M

Effects of Growth Factors and Basement Membrane Proteins on the Phenotype of U-373 MG Glioblastoma Cells as Determined by the Expression of Intermediate Filament Proteins

✍ Sadath Sultana; Rixin Zhou; Madhu S. Sadagopan; Omar Skalli 📂 Article 📅 1998 🏛 American Society for Investigative Pathology 🌐 English ⚖ 887 KB

Inhibition of proliferation and inductio

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level

✍ Manuela Campiglio; Alberta Locatelli; Clelia Olgiati; Nicola Normanno; Giulia So 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 297 KB 👁 2 views

High expression of the epidermal growth factor receptor (EGFR) in breast carcinoma confers a growth advantage to the tumor cells. The EGFR tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') has clinical activity in a wide range of tumor types, although the mechanism(s) by which it exerts its ant